Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
40.68
+1.34 (3.39%)
Nov 21, 2024, 1:29 PM EST - Market open
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for XENE stock have an average target of 57.3, with a low estimate of 49 and a high estimate of 65. The average target predicts an increase of 40.86% from the current stock price of 40.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for XENE stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 5 | 5 | 5 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +30.29% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +47.49% | Nov 13, 2024 |
| Raymond James | Raymond James | Buy Initiates $50 | Buy | Initiates | $50 | +22.91% | Oct 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $53 | Strong Buy | Initiates | $53 | +30.29% | Oct 1, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $55 | Buy | Reiterates | $55 | +35.20% | Sep 3, 2024 |
Financial Forecast
Revenue This Year
318.75K
Revenue Next Year
5.42M
from 318.75K
Increased by 1,600.08%
EPS This Year
-3.14
from -2.73
EPS Next Year
-3.63
from -3.14
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.3M | 78.8M | 113.5M | ||
| Avg | 318,750 | 5.4M | 48.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 24,605.9% | 1,995.0% | ||
| Avg | - | 1,600.1% | 795.3% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.73 | -2.48 | -2.90 | ||
| Avg | -3.14 | -3.63 | -3.89 | ||
| Low | -3.37 | -4.18 | -4.99 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.